

2420MO

Effects of prostate radiotherapy (RT) on synchronous, metastatic, hormone-sensitive prostate cancer (mHSPC): STOPCAP meta-analysis of individual participant data (IPD)

P.J. Godolphin¹, S. Burdett¹, A. Sachdeva², L. Rydzewska¹, L.R. Murphy¹, S. Foulon³, L. Boevé⁴, C. Parker⁵, A. Bossi⁶, G. van Andel⁴, G. Attard⁷, N.W. Clarke⁸, K. Fizazi⁹, S. Gillessen¹⁰, N.D. James¹¹, D. Matheson¹², R. Oldroyd¹³, C. Sweeney¹⁴, B. Tombal¹⁵, J.F. Tierney¹

¹ MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology-UCL, London, United Kingdom, ² Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom, ³ Biostatistics and Epidemiology Department, Gustave Roussy - Cancer Campus, Villejuif, France, ⁴ Department of Urology, OLVG, Amsterdam, Netherlands, ⁵ Department of Urology, The Royal Marsden Hospital (Sutton), Sutton, United Kingdom, ⁶ Radiotherapy Department, Gustave Roussy - Cancer Campus, Villejuif, France, ⁷ Research Department of Oncology, University College London, London, United Kingdom, ⁸ Urology Dept., The Christie NHS Foundation Trust, Manchester, United Kingdom, ⁹ Cancer Medicine Department, Institut Gustave Roussy, Villejuif, France, ¹⁰ Medical Oncology Department, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland, ¹¹ Prostate and Bladder Cancer Research Department, ICR - Institute of Cancer Research, London, United Kingdom, ¹² Faculty of Education, Health and Wellbeing, University Of Wolverhampton - Walsall Campus, Walsall, United Kingdom, ¹³ Faculty of Education, Health and Wellbeing, Institute of Clinical Trials and Methodology-UCL, London, United Kingdom, ¹⁴ South Australian Immunogenomics Cancer Institute, The University of Adelaide, Adelaide, Australia ¹⁵ Urology department, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, Belgium

Background

Based on the PEACE-1 and STAMPEDE trials, the consensus is that low volume, synchronous mHSPC is treated with prostate RT, an androgen receptor pathway inhibitor (ARPI) and androgen deprivation therapy. Docetaxel, with or without an ARPI, is generally not recommended. To more precisely assess effects of prostate RT, we sought updated IPD from eligible randomised trials.

Methods

Were registered in protocol CRD420251038299. Main outcomes are overall survival (OS), progression free-survival (PFS: clinical or radiological progression or death) and symptomatic local events (SLE: TURP, urinary catheterisation, ureteric stent or nephrostomy). We examined prostate RT effects using 2-stage, common-effect meta-analysis. Main effects were based on OS. Interactions were based on PFS (to increase power), then OS if interactions were found. Absolute effects were derived from flexible parametric models. All analyses were adjusted for a core set of covariates.

Results

To date, IPD from PEACE-1 and STAMPEDE are included (88% of eligible men). Overall, prostate RT did not improve OS (HR=0.93, 95% CI 0.85-1.02, p=0.11), but did prolong PFS (HR=0.88, 95% CI 0.81-0.96, p=0.003). Effects of prostate RT varied by disease volume on PFS and OS (Interaction (Int) p=0.002; p=0.009) and number of bone metastases on PFS (Int p=0.009), less so OS (p=0.14). Benefits were confined to men with low volume disease, irrespective of docetaxel use. Also, benefits were limited to men with ≤4 bone metastases, particularly if visceral metastases were absent. Effects of prostate RT did not vary clearly by other patient characteristics. Table: 2420MO

Relative (and absolute effects) on OS by:

Low volume	HR=0.79, 95% CI 0.67-0.93, p=0.005 (7.7% OS difference at 5 years)	≤ 4 bone mets	HR=0.84, 95% CI 0.72-0.98, p=0.030 (4.9% OS difference at 5 years)
High volume	HR=1.03, 95% CI 0.92-1.16, p=0.59 (-1.9% OS difference at 5 years)	5+ bone mets	HE=0.98, 95% CI 0.86-1.10, p=0.68 (-0.3% difference at 5 years)
<i>Excluding pts that received docetaxel (exploratory)</i>			
<i>Excluding pts with visceral mets (exploratory)</i>			
Low volume	HR=0.82, 95% CI 0.68-0.99, p=0.037	≤ 4 bone mets	HR=0.79, 95% CI 0.66-0.95, p=0.014

Conclusions

These data suggest no overall OS benefit in the synchronous mHSPC population, but a 21% relative reduction in risk of death in those with low volume, metastatic disease. We will present updated results, including IPD from HORRAD and the SLE outcome, to refine treatment

recommendations for mHSPC.

Legal entity responsible for the study

The authors.

Funding

Prostate Cancer UK (MA-TIA23-007); UK Research and Innovation Medical Research Council (MC_UU_00004/06) UNIT FUNDING.

Disclosure

A. Sachdeva: Financial Interests, Personal, Invited Speaker: Ipsen; Non-Financial Interests, Other, Associate Member: EAU Prostate Cancer Guidelines Panel. S. Foulon: Financial Interests, Institutional, Advisory Board, Participation to the advisory board (statistical advice) of an epidemiological study performed by Gilead on real world data (medico-administrative data): Review and validation of the study protocol, validation of the study population, as well as the review and validation of the results and of the study report.: Gilead. C. Parker: Financial Interests, Personal, Advisory Board, May 2023: Blue Earth Therapeutics. G. Attard: Financial Interests, Personal, Invited Speaker: Janssen, Astellas, AstraZeneca, Sanofi; Financial Interests, Personal, Advisory Board: Janssen, Astellas, Novartis, Bayer, AstraZeneca, Pfizer, Sanofi, Sapience, Orion, Novartis, Blue Earth Therapeutics; Financial Interests, Personal, Other, Travel, accommodations, expenses: Amgen, Merck Serono, Pfizer; Financial Interests, Personal, Royalties, Included in list of rewards to discoverers of abiraterone: Institute of Cancer Research; Financial Interests, Institutional, Advisory Board: Artera, Veracyte; Financial Interests, Institutional, Research Grant: Janssen, Astellas, Novartis; Financial Interests, Institutional, Coordinating PI: Janssen; Financial Interests, Institutional, Local PI: Novartis, Pfizer; Financial Interests, Institutional, Funding: Blue Earth Therapeutics, Vercyte; Non-Financial Interests, Principal Investigator: Janssen, Astellas; Non-Financial Interests, Advisory Role: Janssen, AstraZeneca, Amgen, Bayer, Blue Earth Therapeutics, Merck, Merck Serono, Novartis, Pfizer; Non-Financial Interests, Project Lead: Artera, Veracyte. N.W. Clarke: Financial Interests, Invited Speaker: Astellas, Bayer, Janssen, Novartis AAA, Ipsen, MedScape; Financial Interests, Other, Travel/Meetings: Astellas, Bayer, Janssen, Novartis, Ipsen. K. Fizazi: Financial Interests, Institutional, Advisory Board: Astellas, Bayer, Janssen, MSD, AstraZeneca, Novartis/AAA, Pfizer, Daiichi Sankyo; Financial Interests, Institutional, Invited Speaker: Astellas, Bayer, Janssen, MSD, AstraZeneca, Novartis, Pfizer; Financial Interests, Personal, Invited Speaker: Hopes, Tactics, PeerVoice, Research to Practice, Epics, Urotoday, ED Med resources, Medscape, Health podcast, Clinical care options, Oseus, e-china health, Darman Strategik Numerik, Cancerodigest; Financial Interests, Personal, Other, Comments on new data: Cancer expert now; Financial Interests, Personal, Advisory Board: Axiom, Arivan, Access infinity, Globe life sciences, Reach market research, MD to market, PSI; Financial Interests, Institutional, Research Grant, Trial chair: Pfizer, Bayer, AstraZeneca, Orion, MSD, BMS, Janssen; Financial Interests, Institutional, Coordinating PI, Trial chair: Novartis; Non-Financial Interests, Principal Investigator, Chair of the 7DX phase 3 trial: BMS; Non-Financial Interests, Principal Investigator, Chair of the Docetaxel-pembrolizumab phase 3 trial: Merck; Non-Financial Interests, Principal Investigator, Chair of the Darolutamide BCR phase 3 trial: Bayer; Non-Financial Interests, Principal Investigator, Chair of the PSMAfore phase 3 trial: AAA/Novartis; Non-Financial Interests, Principal Investigator, Chair of the CYPIDES ODM-208 Phase I-II trial: Orion; Non-Financial Interests, Principal Investigator, Chair of the STESIDES ODM-209 Phase I-II trial: Orion; Non-Financial Interests, Principal Investigator, Chair of the CAPITELLO 281 phase 3 trial: AstraZeneca; Non-Financial Interests, Principal Investigator, Chair of the TALAPRO-2 and TALAPRO-3 phase 3 trials: Pfizer; Non-Financial Interests, Principal Investigator, Chair of the RADIANT phase 3 trial: Bayer; Non-Financial Interests, Principal Investigator, Chair of the TRITON-3 phase 3 trial: Clovis. S. Gillessen: Financial Interests, Institutional, Invited Speaker, 02/2023: ASCO GU; Financial Interests, Institutional, Invited Speaker, 09/2023: AdMeTech Foundation; Financial Interests, Institutional, Advisory Board, 02/2025: Amgen, Merck; Financial Interests, Institutional, Advisory Board, 06/2024: Astellas; Financial Interests, Institutional, Advisory Board, 2024: Avalere Health; Financial Interests, Institutional, Advisory Board, I-One Prostate Cancer ESMO 09/2024: Avalere Health; Financial Interests, Institutional, Advisory Board, 02/2023: BMS, Daiichi Sankyo; Financial Interests, Institutional, Other, Consultant service 01.2025-12.2026: BMS; Financial Interests, Institutional, Advisory Board, 02/2023, 11/2023, 06/2024, 09/2024, 11/2024: Bayer; Financial Interests, Personal, Other, Travel support 06/2023, 06/2024: Bayer; Financial Interests, Institutional, Advisory Board, 06/2023: Boehringer Ingelheim Ingelheim; Financial Interests, Institutional, Invited Speaker, 11/2023, 09/2024, 02/2025: EPG Health; Financial Interests, Personal, Invited Speaker, ESMO Preceptorship prostate cancer 12/2023: ESMO; Financial Interests, Institutional, Invited Speaker, ESMO Preceptorship prostate cancer 12/2024: ESMO; Financial Interests, Personal, Other, Travel support 01/2024: Gilead; Financial Interests, Institutional, Advisory Board, 07/2023: Innomedica; Financial Interests, Institutional, Invited Speaker, 01/2024: Intellisphere LLC; Financial Interests, Personal, Other, Travel Support 01/2024: Intellisphere LLC; Financial Interests, Institutional, Advisory Board, 09/2023, 02/2024: Ipsen; Financial Interests, Institutional, Other, Scientific Advisory Committee, 07/2024: LinkinVax; Financial Interests, Institutional, Advisory Board, 03/2024: Macrogenics; Financial Interests, Institutional, Invited Speaker, Speaker Oncosummit 02/2024: Meister ConCept GmbH; Financial Interests, Personal, Invited Speaker, Speaker OncoSummit 2023: Meister ConCept GmbH; Financial Interests, Institutional, Advisory Board, 07/2024, 11/2024: Novartis; Financial Interests, Institutional, Invited Speaker, Speaker Pro.State of the art 01.2025: Orikata; Financial Interests, Institutional, Other, Interview 09/2024: PeerVoice; Financial Interests, Institutional, Other, Scientific Committee Pfizer Forschungspreis 11/2023: Pfizer; Financial Interests, Institutional, Invited Speaker, 02/2023, 09/2023: SAKK; Financial Interests, Institutional, Invited Speaker, 09/2023, 09/2024: Silvio Grasso Consulting; Financial Interests, Personal, Other, Travel support 02/2025: Johnson & Johnson; Financial Interests, Institutional, Invited Speaker, 01/2025: Medtoday Switzerland; Financial Interests, Personal, Other, Advisory commission 11/2024: University of Applied Sciences and Arts of Southern Switzerland (SUPSI); Financial Interests, Institutional, Invited Speaker, GU Event Apr 2nd, Sao Paulo - Brazil: UroPratica Group in Sao Paulo; Financial Interests,

Personal, Other, Part of a patent for a biomarker, but (for the moment) no income, but I could not write none in the dropdown menu: Proteomedix/Onconetix; Financial Interests, Institutional, Funding, 2021, Unrestricted grant for a Covid related study as co-investigator: Astellas; Non-Financial Interests, Advisory Role, Continuing: ProteoMediX; Non-Financial Interests, Other, Guest engagement agreement 03/2023: ASCO; Non-Financial Interests, Advisory Role, Steering Committee Charter PEACE6-Vulnerable 04/2023: Unicancer; Non-Financial Interests, Other, Senior Executives meeting 05/2024: AstraZeneca; Non-Financial Interests, Advisory Role, Consultat service 01/2025: Pfizer. N.D. James: Financial Interests, Other, Honoraria: Astellas Pharma, Bayer, Janssen, Sanofi; Financial Interests, Advisory Role: Astellas Pharma, Bayer, Clovis Oncology, EUSA Pharma, Janssen, Pfizer, Sanofi; Financial Interests, Speaker's Bureau: Astellas Pharma, AstraZeneca, Ferring, Janssen Oncology, Merck, Pierre Fabre, Sanofi; Financial Interests, Institutional, Research Funding: Astellas Pharma, AstraZeneca, Janssen, Novartis, Pfizer, Sanofi; Financial Interests, Other, Travel, accommodation, expenses: Bayer, Janssen, Sanofi. C. Sweeney: Financial Interests, Personal, Advisory Board, Consultancy: Genentech_Roche, Bayer, Astellas, Pfizer; Financial Interests, Personal, Other, Consultancy: Janssen, MSD, Novartis, Amgen; Financial Interests, Personal, Advisory Board: Point, Cellcentric; Financial Interests, Personal, Advisory Board, Consultant: Advancell; Financial Interests, Personal, Advisory Board, Advisory Boards: BMS; Financial Interests, Personal, Advisory Board, Consulntant: Amphista; Financial Interests, Personal, Stocks/Shares: Leuchemix; Financial Interests, Personal, Stocks/Shares, Consultant: Advancell; Financial Interests, Institutional, Advisory Board, Abiraterone plus cabozantinib: Exelixis; Financial Interests, Institutional, Research Grant: Bayer, Janssen, Astellas, Pfizer, Dendreon, Sanofi. B. Tombal: Financial Interests, Personal, Advisory Board: Astellas, Bayer, Amgen, Janssen, Sanofi, Myovant, Novartis (AAA), Pfizer, Astellas, MSD, AstraZeneca; Financial Interests, Personal, Invited Speaker: Astellas, Amgen, Ferring, ACCORD; Non-Financial Interests, Member of Board of Directors, Past President: European Organisation of Research and Treatment of Cancer (EORTC); Non-Financial Interests, Member of Board of Directors, Education in the field of Oncology: ISSECAM. All other authors have declared no conflicts of interest.